Comparison Between Three (1→3)-β-D-glucan Measurement Kits in Japan for the Diagnosis of Invasive Fungal Infection
暂无分享，去创建一个
Hideyuki Ogata | T. Kikuchi | T. Koya | Mizuho Sato | N. Aoki | M. Hayashi | Yuuki Bamba | H. Moro | Takeshi Koizumi | K. Nagano | M. Hakamata | Sho Shimazu | Akiko Sakagami | Hitomi Cho
[1] C. Beigelman-Aubry,et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[2] H. Wisplinghoff,et al. 1,3‐ß‐D‐glucan concentrations in blood products predict false positive post‐transfusion results , 2016, Mycoses.
[3] R. Krause,et al. Reliability of serum 1,3‐beta‐d‐glucan assay in patients undergoing renal replacement therapy: a review of the literature , 2015, Mycoses.
[4] Y. Niki,et al. Clinical viability of Fungitell, a new (1→3)-β-d-glucan measurement kit, for diagnosis of invasive fungal infection, and comparison with other kits available in Japan , 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[5] J. Perfect,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] S. Kohno,et al. Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes , 1995, The Lancet.